Hillsdale Investment Management Inc. Invests $3.11 Million in Aurinia Pharmaceuticals Inc $AUPH

Hillsdale Investment Management Inc. bought a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) during the first quarter, HoldingsChannel reports. The firm bought 209,900 shares of the biotechnology company’s stock, valued at approximately $3,111,000.

Other large investors have also modified their holdings of the company. BOK Financial Private Wealth Inc. acquired a new position in Aurinia Pharmaceuticals in the fourth quarter worth about $32,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Aurinia Pharmaceuticals during the third quarter valued at approximately $48,000. Kemnay Advisory Services Inc. acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at approximately $82,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Aurinia Pharmaceuticals by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,407 shares of the biotechnology company’s stock worth $102,000 after buying an additional 1,318 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Aurinia Pharmaceuticals by 32.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,034 shares of the biotechnology company’s stock worth $110,000 after buying an additional 3,191 shares during the last quarter. Institutional investors own 36.83% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on AUPH shares. Zacks Research upgraded Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. Weiss Ratings cut Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.25.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $16.10 on Thursday. The company has a market cap of $2.07 billion, a PE ratio of 7.42 and a beta of 1.41. Aurinia Pharmaceuticals Inc has a fifty-two week low of $8.55 and a fifty-two week high of $19.25. The firm has a 50-day simple moving average of $16.01 and a 200 day simple moving average of $15.37. The company has a quick ratio of 5.01, a current ratio of 5.55 and a debt-to-equity ratio of 0.08.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Thursday, May 7th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.07. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. The firm had revenue of $77.71 million for the quarter, compared to analysts’ expectations of $76.98 million. On average, sell-side analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.82 EPS for the current year.

Insider Buying and Selling at Aurinia Pharmaceuticals

In related news, CEO Kevin Tang purchased 206,005 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The shares were acquired at an average cost of $15.28 per share, for a total transaction of $3,147,756.40. Following the transaction, the chief executive officer owned 13,044,106 shares of the company’s stock, valued at $199,313,939.68. This trade represents a 1.60% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders purchased 814,606 shares of company stock worth $12,455,129. 12.20% of the stock is currently owned by corporate insiders.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.